Introduction
The p21-activated protein kinase 1 (Pak1) is a serine/ threonine kinase that is important for a variety of cellular functions, including cell motility, survival, and mitosis (Bokoch, 2003; Vadlamudi and Kumar, 2003) . Pak1 is one of the downstream effectors of the activated Rho GTPases Cdc42 and Rac1 (Manser et al., 1994) . In addition, the expression of constitutively activated Pak1 mimics some of the cytoskeletal structures of the phenotypes of Rho GTPases . Emerging evidence has further implicated the involvement of Pak1 in multiple pathways. For example, Pak1 stimulates the mitogen-activated protein kinases (p42/44 and p38), Jun N-terminal kinase, and nuclear factorkappa B . Pak1 also affects the cell survival pathway by phosphorylating and inactivating the proapoptotic functions of Bad (Schurmann et al., 2000) and by regulating the interactions of dynein light chain 1 and the proapoptotic BH3-only proteinBimL .
Emerging studies have further shown that when Pak1 is in the nuclear compartment, it has a supposed role in chromatin remodeling by phosphorylating the histone H3.3 Vadlamudi et al., 2004) . Pak1 also undergoes phosphorylation during mitosis (Thiel et al., 2002) , is enriched in microtubule-organizing centers (Banerjee et al., 2002) , and induces mitotic spindle abnormalities in breast cancer cells, suggesting that Pak1 plays a role in mitosis as well (Vadlamudi et al., 2000) . Pak1 also interacts with and phosphorylates estrogen receptors (ER). In this setting, Pak1 functions as a coactivator of ER transcriptional activity, suggests it plays a role in growth factor-nuclear receptor crosstalk (Wang et al., 2002; Balasenthil et al., 2004a, b) .
Pak1 is expressed in numerous tissues and is activated by a number of polypeptide factors and extracellular signals in both a GTPase-dependent (via Rac1 or Cdc42) and GTPase-independent manner via its localization to membrane/focal adhesion (Bokoch, 2003) . Pak1 is also activated by lipids, tyrosine kinases, and novel substrates such as filamin and G-proteins Vadlamudi and Kumar, 2003) . The fact that Pak1 can be activated by distinct ligands and its function in multiple signaling pathways suggests that its activity is tightly controlled in cells. However, very little is known about the molecular mechanisms that negatively regulate Pak1 activity in vivo. Our purpose in this study was, therefore, to learn more about these mechanisms.
To identify novel Pak1-interacting proteins that negatively regulate Pak1 functions, we performed a yeast two-hybrid screen of a human mammary gland cDNA expression library. The findings led us to identify a cysteine-rich inhibitor of Pak1 (CRIPak; Genbank Accession number NM_175918) as a Pak1-interacting protein. By using various biochemical, molecular, and cell biology approaches, we have provided evidence that CRIPak is a novel inhibitor of Pak1.
Results

Identification of CRIPak as a Pak1 novel interacting protein
The yeast two-hybrid screening of the mammary gland cDNA expression library identified 200 positive interactors. Sequencing revealed that one of the positive interacting clones was a novel protein (Genbank Accession number NP_787114) that contained an open-reading frame of 446 amino acids and lacked any homology with known proteins (Figure 1a) . A motif scan revealed that the protein was similar in three areas to the trypsin inhibitor-like, cysteine-rich domain (motif Accession number PF01826). In addition, its amino-acid sequence showed 13 potential zinc-finger domains ( Figure 1b ). As this protein was unusually rich in cysteine residues, we named it CRIPak.
We compared CRIPak sequence with the human genome that revealed that CRIPak has been localized to 4p16.3 and is an intronless gene with an entire reading frame encoded by a single exon. A search of the expressed sequence tag (EST) databases revealed that CRIPak is widely expressed in a number of tissues, including the lymph node, stomach, brain, ovary, testis, uterus, mammary gland, lung, prostate, pancreas, bone, and kidney. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed that CRIPak expresses in all the human cancer cell lines tested here, including breast cancer cells (Figure 1c ). Northern blot analysis also revealed that CRIPak was widely expressed in a number of tissues. It was most highly expressed in the trachea, prostate, and adrenal glands (Figure 1d ). CRIPak Interacts with Pak1 in vivo and in vitro To confirm the interaction in the yeast two-hybrid screen, we performed one-on-one interaction by using a yeast test strain that stably expresses the nutritional reporter gene HIS3 under the control of the Gal4 promoter. Cotransformation of a yeast two-hybrid test strain (AH109, Clontech) was performed with vectors expressing Gal4 DNA-binding domain Pak1 fusion protein (GBD-Pak1) and Gal4 activation domain CRIPak fusion protein (GAD-CRIPak). GBD-PAK1 interacts with GAD-CRIPak in yeast cells as shown by their growth on the media lacking histidine (Figure 2a ). To test whether CRIPak can bind directly to Pak1 in vitro, Pak1 was expressed as a GST fusion protein in bacteria and tested for interaction with in vitrotranscribed and -translated [ 35 S] methionine-labeled CRIPak. GST alone failed to bind to CRIPak, whereas the GST-Pak1 fusion protein did bind to labeled CRIPak (Figure 2b ), suggesting that CRIPak is able to interact with Pak1 in vitro. To further demonstrate that CRIPak interacts with Pak1 in mammalian cells, we transiently coexpressed GST epitope-tagged CRIPak and myc epitope-tagged Pak1 in COS7 cells and assayed for complex formation by using immunoprecipitation followed by western analysis. As shown in Figure 2c 
CRIPak inhibits Pak1 activity
Since Pak1 is a serine/threonine kinase, and because CRIPak interacted with Pak1 both in vitro and in vivo, we examined whether CRIPak is a substrate of Pak1. An in vitro kinase assay using a purified Pak1 enzyme and GST-CRIPak as a substrate, it showed that CRIPak is not a substrate of Pak1 (Figure 4a ). Curiously, in these assays we observed that Pak1 autophosphorylation was reduced when CRIPak was added to the reaction. As autophosphorylation reflect a proteins activation state, these results raised the possibility that CRIPak inhibits the activity of Pak1. To confirm the inhibitory effect of CRIPak on Pak1 activation, we tested whether CRIPak could inhibit Pak1 kinase in vitro by incubating Pak1 with increasing amounts of recombinant GST-CRIPak. As shown in Figure 4b , CRIPak inhibited Pak1 in a dose-dependent manner. In the presence of CRIPak, Pak1's ability to phosphorylate myelin basic protein (MBP) in a kinase assay also decreased in a dosedependent manner (Figure 4b ).
We next examined whether CRIPak inhibits Pak1 activity in vivo by performing a cotransfection-based assay. COS7 cells were cotransfected with Pak1 and CRIPak in the presence or absence of serum. As a second method of activation of Pak1, we cotransfected Pak1 with or without dominant active Cdc42 and CRIPak. Cells were lysed and Pak1 was immunoprecipitated and assayed for kinase activity by an immune complex kinase assay in which MBP acted as a substrate. The treatment of Pak1-transfected cells with serum or the cotransfection of Pak1 with the dominant active mutant of Cdc42 (Cdc42V12) 
CRIPak modulates Pak1-induced activation of ERs
Recent evidence implicated Pak1 in the ER signaling. Pak1 phosphorylates ER on Ser305 and activate ER in a ligand-independent manner (Wang et al., 2002; Balasenthil et al., 2004a, b) . Since CRIPak inhibits Pak1, we examined whether CRIPak has any role in the Pak1-mediated upregulation of the ER pathway. MCF7 cells were cotransfected with Pak1 and ERE-luciferase reporter gene with or without CRIPak. As shown in Figure 5a, overexpression of Pak1 increased EREluciferase activity (five-fold) in the absence of estrogen. However, cotransfection of CRIPak substantially reduced Pak1's ability to activate ERE reporter gene. Similarly, CRIPak blocked the Cdc42-or Rac1-mediated increase in the Pak1-mediated ERE reporter gene activity (Figure 5b and c ). These data demonstrate that CRIPak suppresses Pak1-mediated ER activation by inhibiting Pak1.
Since CRIPak inhibited ER reporter gene activity in the presence of activated Pak1 (Figure 5 ), we next examined the potential influence of estrogen or Pak1 upon this inhibition. We found that CRIPak inhibits ERE reporter gene activity both in the presence or absence of estrogen or exogenous Pak1 (Figure 6a) . Similarly, ERE reporter activity was inhibited by knockdown of the endogenous Pak1 in cells expressing CRIPak (Figure 6b ). Together, these results suggested that CRIPak may inhibit ERE reporter activity in both Pak1-dependent and -independent manner.
CRIPak is translocated to the nuclear compartment upon hormonal treatment Since ER transcriptional activation primarily occurs in the nuclear compartment, by using confocal microscopy, we examined whether estrogen promotes the translocation of CRIPak to the nuclear compartment. In the absence of estrogen, CRIPak was predominantly localized to the cytoplasm. In the presence of estrogen, CRIPak was localized to the nuclear compartment. (Figure 7a ) CRIPak nuclear localization was blocked by anti-estrogen ICI-182780. (Figure 7b, c) These results suggest that ER signaling promotes the nuclear localization of CRIPak. We therefore examined whether CRIPak colocalized with ER. Confocal analysis revealed the colocalization of CRIPak and ER in the presence of estrogen. As EST data showed the wide expression of CRIPak in hormonal-responsive tissues such as the mammary gland, and since CRIPak inhibited the Pak1-mediated activation of nuclear receptor signaling, we examined whether CRIPak expression is upregulated by hormone. The model cells we used were MCF7 breast cancer cells, which are hypersensitive to estrogen (Song et al., 2002) . MCF7 cells were treated with estrogen for 6 h had increased levels of CRIPak mRNA compared with untreated cells (Figure 7e ). Since CRIPak expression was increased by estrogen treatment, we examined the effect of estrogen stimulation on CRIPak-ERa interaction. MCF7 cells were transiently transfected with ERa and GST-CRIPak and treated with estrogen in the presence or absence of antiestrogen ICI-182780 for last 6 h. Cell lysates were immunoprecipitated with GST and immunoblotted with ERa and GST antibodies. We found that CRIPak binds to ERa in a ligand-sensitive manner, as these effects were blocked by anti-estrogen ICI-182780 (Figure 7f ). These results suggest that CRIPak is an inhibitor of the Pak1 activation linked with nuclear receptor signaling and that CRIPak expression and interaction are modulated by hormone.
CRIPak modulates Pak1 activity
Since CRIPak inhibits Pak1 activity, we next examined the effect of endogenous CRIPak upon the status of Pak1 activity. To test this possibility, we knocked down the endogenous CRIPak in MCF7 cells by small interfering RNA (siRNA) (Figure 8a ). As expected, downregulation of the endogenous CRIPak resulted in an increased Pak1 activity (Figure 8b ). Since cytoskeleton remodeling represents one of the major characteristics of Pak1 activation, we next showed that downregulation of CRIPak also leads to a substantial increase in the formation of motile structures (Figure 8c ), presumably due to elevated Pak1 activity. As a second readout of phenotypic effects of the endogenous CRIPak downregulation, we also examined the influence of CRIPak siRNA on Pak1-mediated ER transactivation. We found that indeed a reduction in the level of CRIPak was accompanied by a significant increases in both basal and estrogen-induced ER transactivation activity (Figure 8d ). Collectively, these findings suggest that Pak1 activity and functions may be negatively regulated by CRIPak.
Discussion
Pak1 is widely expressed in numerous tissues and is activated by a number of growth factors and extracellular signals (Wang et al., 2002; Bokoch, 2003; Balasenthil et al., 2004a, b) . Emerging data have shown that proteins involved in diverse pathways such as MLC, filamin, stathmin, MEK, histone H3.3, p41-Arc, ER, CTBP, and PGM are Pak1 substrates . The participation of Pak1 in multiple pathways also suggests that the temporal/spatial regulation of Pak1 activity is essential for the successful execution of its effector functions. By using a yeast two-hybrid-based screen assay, we identified CRIPak as a novel Pak1-interacting protein. We further demonstrated that CRIPak is widely expressed in a number of tissues and inhibits Pak1 activity both in vitro and in vivo.
To date, only a fewer studies have shown the existence of natural inhibitors/negative regulators of Pak1 activity. For example, human protein inhibitor of Pak1 is a novel protein that interacts with Pak1 and inhibits the Cdc42/Rac1-stimulated kinase activity through its interactions with the N-terminal regulatory domains of Pak1 (Xia et al., 2001) . The tumor suppressor gene NF2/ merlin inhibits Pak1 activity by directly interacting with the Pak1 N-terminal region containing the p21 GTPasebinding domain and by inhibiting the recruitment of Pak1 to focal adhesions (Kissil et al., 2003) . Nischarin, an alpha5beta1 integrin-binding partner, interacts with the carboxy-terminal domain of Pak1 and strongly inhibits the ability of Pak1 to phosphorylate substrates (Alahari et al., 2004) . Our results suggest that CRIPak is another novel regulator of Pak1, it interacts with the Pak1 N-terminal regulatory domain and inhibits its kinase activity. Thus, CRIPak can be added to the growing list of Pak1-negative regulators in vivo.
The activation of Pak1 by Cdc42 and Rac1 was inhibited by CRIPak under physiological conditions. Such inhibition affected the Pak1-mediated downstream activation of pathways such as LIM kinase (Edwards et al., 1999) and ER (Wang et al., 2002) . The molecular mechanism by which CRIPak might inhibit Pak1-activated pathways is not clear; however, it may involve several different mechanisms. Since the CRIPak binding site in Pak1 has been localized to amino acids 132-270, which partially overlap with the Pak1 inhibitory domain (amino acids 75-149), CRIPak's binding to Pak1 may enhance the function of the autoinhibitory domain and thus reduce the activation of Pak1. Alternatively, because the CRIPak binding site overlaps with the PIX binding region in Pak1, some of the CRIPakmediated inhibition could be due to its potential interference with the binding of other regulatory proteins such as PIX (Daniels et al., 1999; Ku et al., 2001) . In addition, CRIPak contains three trypsin inhibitor-like, cysteine-rich TIL domains. These domains are in a number of protease inhibitors and contain 10 cysteine residues that form five disulfite bonds. Two of these inhibitory domains are close to the Pak1 binding site in CRIPak. Future studies are (c) MCF-7 cells were transfected with control siRNA or CRIPak siRNA, and cells were stained for actin remodeling using Alexa Fluor 488-phalloidin. CRIPak siRNA induced more lamellipodia structures in the leading edge, indicated by arrows and more ruffles, indicated by arrowheads. In control siRNA-treated cells, more stress fibers were observed and more focal contacts. (d) MCF7 cells were cotransfected with ERE reporter system with or without Pak1 or activated Cdc42. Control or CRIPak siRNA (100 nM final concentration) were transfected 24 h before ERE reporter gene transfection at 48 h post-transfection. Cells were treated with or without estrogen treatment for 15 h before lysis. required to reveal the mechanism of CRIPak-mediated inhibition and to see whether TIL domains contribute to the inhibition of Pak1. It is also possible that CRIPak has an additional function as a protease inhibitor and that the interaction of Pak1 with CRIPak facilitates Pak1's interaction with its substrates.
Several recent studies have suggested that Pak1 is involved in human cancers (Vadlamudi and Kumar, 2003) . Preferential amplification of gene copy number gains of Pak1 has also been reported (Schraml et al., 2003) . Pak1 expression is deregulated in breast cancer (Balasenthil et al., 2004a, b) and colorectal cancer (Carter et al., 2004) . Since Pak1 activation promotes angiogenesis, cell survival, and cell motility, deregulation of Pak1 activity may promote the survival and metastasis of cancer cells (Vadlamudi and Kumar, 2003) . In a physiological contest, Pak1-negative regulators such as CRIPak might help deregulated Pak1 activation. Interestingly, CRIPak has been localized to chromosome 4p16.3, which is frequently deleted in breast carcinomas (Shivapurkar et al., 1999) . These findings raise the possibility that the loss of CRIPak in breast cancer may indirectly increase the activation of Pak1 for an extended period of time and, thus, may indirectly contribute to breast tumorigenesis.
Amplification of loci present on band q13 of human chromosome 11 is a feature of a subset of ER-positive breast carcinomas prone to metastasis and Pak1 is one of the genes in these loci (Bekri et al., 1997) . Pak1 also interacts with ER and functions as a coactivator of ER transcriptional activity (Wang et al., 2002) . Pak1 directly phosphorylates ER at Ser305 and promotes ER transactivation functions that are independent of estrogen (Balasenthil et al., 2004a, b) . Our findings showed that CRIPak inhibits Pak1-mediated ER transactivation functions, that 17b-estradiol has the ability to induce expression of CRIPak, that ER signaling may potentiate nuclear localization of CRIPak, and that CRIPak and ER are colocalized in the presence of estrogen. These findings demonstrate that CRIPak may function as a negative regulator of hormonal response and that it may have a role as a feedback mechanism of ER activation. It is also possible that the loss of CRIPak in breast tumors might contribute to hormonal independence.
In summary, we identified CRIPak as a novel Pak1-interacting protein. Our data suggest that CRIPak is widely expressed in a number of tissues and that it negatively regulates Pak1 kinase activity. CRIPak expression is upregulated by hormones, associates with ER, and may play a role as a feed back mechanism of hormonal response.
Materials and methods
Cell cultures and reagents MCF7, breast cancer cells, and COS7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12 (1:1) and supplemented with 10% fetal calf serum. An antibody against the T7-tag was purchased from Novagen (Madison, WI, USA) and a c-myc tag was purchased from Lab Vision Corporation Yeast two-hybrid library screening Pak1 baits were constructed by amplifying amino acids 1-270 and 271-545 by a PCR, and then subcloned them into Gal4-binding domain via a pGBD vector (Clontech, Palo Alto, CA, USA). A mammary gland cDNA library fused to the Gal4 activation domain (Clontech) and was screened by using Nterminal Pak1 (amino acids 1-270) as the bait in accordance with the manufacturer's instructions. A total of 2 Â 10 6 clones were screened. Positive interactors were verified by one-onone transformations. This was followed by the selection of cells that grow on agar plates lacking adenosine, histidine, leucine, and tryptophan.
Plasmid construction
To generate glutathione S-transferase (GST) and T7 epitopetagged CRIPak, a cDNA fragment containing complete openreading frame of CRIPak was released with ApoI (blunt end)-XhoI and ligated into EcoRI (blunt end)-XhoI sites of pGEX-5X-2 (Amersham Biosciences Corp., Piscataway, NJ, USA) and pcDNA 3.1 A (Invitrogen Corporation, Carlsbad, CA, USA) vectors, respectively. CRIPak deletion constructs were generated by using internal restriction sites and by subcloning into the pGEX-5X vector. The pEBG-CRIPak (GST-tagged mammalian expression vector) was generated by subcloning a CRIPak open-reading frame from CRIPak in pcDNA3.1 vector using HindIII (blunt ended)-NotI and by ligating at ClaI (blunt ended)-NotI sites in the pEBG-vector.
Pak1 kinase assay: in vitro Pak1 kinase assays were performed in which myelin basic protein (MBP) or GST-CRIPak protein was used in HEPES buffer (50 mM HEPES, 10 mM MgCl 2 , 2 mM MnCl 2 , 0.2 mM DTT) containing 100 ng of purified GST-Pak1 enzyme, 10 mCi of [g-32 P] ATP, and 25 mM cold ATP. Purified human Pak1 enzyme (#GLO-110-E100) was purchased from Alexis Biochemicals (San Diego, CA, USA).
GST pull-down assays
The in vitro transcription and translation of the Pak1 and CRIPak proteins was performed by using the TNT T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI, USA) as described previously .
Northern blotting and RT-PCR
A premade poly-A þ RNA blot from human adrenal gland, bladder, bone marrow, brain (whole), lymph node, mammary gland, prostate, spinal cord, stomach, thyroid, trachea, and uterus tissues was purchased from Clontech. Expression of CRIPak was verified by hybridizing it with a radioactive CRIPak cDNA fragment. The blot was reprobed with betaactin. For the RT-PCR studies, total RNA was isolated by using TRIZOL (Invitrogen) and RT-PCR was performed by using a RT-PCR kit (Promega). The forward primer was 5 0 -CTCACACACGTGCCCATGTGGAGT-3 0 , and the reverse primer was 5 0 -TATCTCGAGGTGCAGAGAAATA TAAAAGGGA-3 0 used for amplification of CRIPak.
Immunoprecipitation and Western blotting
For the immunoprecipitation experiments, MCF7 cells were transiently transfected with 1 mg of GST-CRIPak and myc-Pak1, or of pcDNA (control vector) and GST-CRIPak using Fugene6 Transfection Reagent (Roche Molecular Systems Inc., Branchburg, NJ, USA). Cells were lysed after 48 h of transfection in NP-40 lysis buffer and immunoprecipitated with GST beads for 4 h. Immunoprecipitates were analysed by Western blot utilizing T7, and c-myc epitope antibodies.
Reporter gene assays Cells were maintained in DMEM-F12 (1:1) that was supplemented with 10% fetal calf serum. For ERE reporter gene transient transfections, cells were cultured in a medium without phenol red that contained 3% charcoal-stripped serum for 24 to 36 h. Transient transfection with the appropriate plasmids was performed by using Fugene6 (Roche Molecular Systems Inc., Branchburg, NJ, USA) according to the manufacturer's instructions. Promoter assays were performed at 48 h after transfection as described previously (Talukder et al., 2004) Immunofluorescence and confocal studies The cellular location of proteins was determined by using indirect immunofluorescence, as described previously . Cells were incubated with primary antibodies for 2 h, washed three times in PBS, and then incubated with secondary antibodies labeled with Alexa Fluor 546 (red), 633 (blue), or 488 (green) (Molecular Probes Inc., Eugene, OR, USA). The procedure involved processing the same section for each detector (the two excitations corresponding to 546 and to 488 or 633 nm) and making a pixel-by-pixel comparison.
Interference ofPak1 and CRIPak expression by siRNA We used siRNA designed by Cell Signaling to target human Pak1 (catalog number, M-003521-03) and by Qiagen to target human CRIPak (catalog number, M-018504-00) sequences. As a control, we used a commercially available nonspecific random siRNA. MCF7 cells were seeded at 50% density the day before transfection in six-well plates. On the day of transfection, cells changed to antibiotic-free 10% serum or 3% DCC medium (for estrogen treatment). Transfections were performed by using Oligofectamine reagent (Invitrogen) according to the manufacturer's instructions with 12 ml of 10 mM siRNA and 4 ml of Oligofectamine reagent/well in sixwell plate (100 nM final concentration). For estrogen treatment, cells were transfected with siRNA in 3% DCC serum. After 60 h, cells were treated for 15 h with estrogen (10
and total RNA was analysed by RT-PCR. For luciferase assay, cells were retransfected after 24 h of siRNA transfection with ERE-luciferase plus other plasmids at 3% DCC medium and kept for another 48 h including treatment with estrogen during the last 15 h before harvesting.
